News | August 12, 2024
Novo Nordisk's H1 sales increased by 24% in Danish kroner
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
The inspection was concluded with zero observations
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Subscribe To Our Newsletter & Stay Updated
